Novavax, Inc. (NVAX)
NASDAQ: NVAX · IEX Real-Time Price · USD
-1.39 (-9.65%)
At close: May 17, 2024, 4:00 PM
+0.09 (0.69%)
After-hours: May 17, 2024, 7:59 PM EDT

Company Description

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.

It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.

The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.
Novavax logo
Country United States
Founded 1987
IPO Date Dec 5, 1995
Industry Biotechnology
Sector Healthcare
Employees 1,543
CEO John Charles Jacobs M.B.A.

Contact Details

700 Quince Orchard Road
Gaithersburg, Maryland 20878
United States
Phone 240-268-2000

Stock Details

Ticker Symbol NVAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001000694
CUSIP Number 670002401
ISIN Number US6700024010
Employer ID 22-2816046
SIC Code 2836

Key Executives

Name Position
John Joseph Trizzino B.S., M.B.A. President and Chief Operating Officer
James Patrick Kelly C.F.A. Executive Vice President, Chief Financial Officer and Treasurer
Stanley Charles Erck Advisor
John Charles Jacobs M.B.A. Chief Executive Officer and Director
Richard P. Crowley Executive Vice President and Chief Operating Officer
Troy Morgan Esq., J.D. Senior Vice President and Chief Compliance Officer
Mark Casey Executive Vice President, Chief Legal Officer and Corporate Secretary
Erika S. Trahan Associate Director of Investor and Public Relations
Ian J. Watkins Executive Vice President and Chief Human Resources Officer
Silvia Taylor M.B.A. Executive Vice President and Chief Corporate Affairs and Advocacy Officer

Latest SEC Filings

Date Type Title
May 14, 2024 144 Filing
May 13, 2024 DFAN14A Filing
May 13, 2024 8-K Current Report
May 10, 2024 8-K Current Report
May 10, 2024 10-Q Quarterly Report
May 8, 2024 DFAN14A Filing
May 7, 2024 DFAN14A Filing
May 7, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
May 6, 2024 DFAN14A Filing
May 6, 2024 PREC14A Filing